As of close of business last night, Guardant Health Inc’s stock clocked out at $17.45, down -1.63% from its previous closing price of $17.74. In other words, the price has decreased by -$0.29 from its previous closing price. On the day, 1837883 shares were traded. GH stock price reached its highest trading level at $17.97 during the session, while it also had its lowest trading level at $17.40.
Ratios:
To gain a deeper understanding of GH’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.24 and its Current Ratio is at 6.54. In the meantime, Its Debt-to-Equity ratio is 8.53 whereas as Long-Term Debt/Eq ratio is at 8.36.
Raymond James Upgraded its Mkt Perform to Outperform on November 13, 2023, while the target price for the stock was maintained at $27.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Joyce Meghan V. sold 100 shares for $19.05 per share. The transaction valued at 1,905 led to the insider holds 4,521 shares of the business.
Joyce Meghan V. sold 100 shares of GH for $2,634 on Dec 04 ’23. The Director now owns 4,422 shares after completing the transaction at $26.34 per share. On Dec 01 ’23, another insider, Kalia Kumud, who serves as the Chief Information Officer of the company, sold 5,800 shares for $26.37 each. As a result, the insider received 152,954 and left with 5,926 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 2.16B and an Enterprise Value of 2.34B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.77 while its Price-to-Book (P/B) ratio in mrq is 13.38. Its current Enterprise Value per Revenue stands at 4.16 whereas that against EBITDA is -5.41.
Stock Price History:
Over the past 52 weeks, GH has reached a high of $41.06, while it has fallen to a 52-week low of $17.65. The 50-Day Moving Average of the stock is 21.73, while the 200-Day Moving Average is calculated to be 28.86.
Shares Statistics:
It appears that GH traded 1.64M shares on average per day over the past three months and 1.67M shares per day over the past ten days. A total of 121.63M shares are outstanding, with a floating share count of 115.91M. Insiders hold about 4.77% of the company’s shares, while institutions hold 92.30% stake in the company. Shares short for GH as of Feb 29, 2024 were 7.05M with a Short Ratio of 4.31, compared to 5.54M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.79% and a Short% of Float of 6.04%.
Earnings Estimates
As of right now, 18 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.83 for the current quarter, with a high estimate of -$0.66 and a low estimate of -$1.04, while EPS last year was -$1.3. The consensus estimate for the next quarter is -$0.8, with high estimates of -$0.62 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.47 and -$3.81 for the fiscal current year, implying an average EPS of -$3.15. EPS for the following year is -$2.89, with 20 analysts recommending between -$1.85 and -$3.48.
Revenue Estimates
In the current quarter, 18 analysts expect revenue to total $150.68M. It ranges from a high estimate of $161.9M to a low estimate of $147M. As of the current estimate, Guardant Health Inc’s year-ago sales were $128.71M, an estimated increase of 17.10% from the year-ago figure. For the next quarter, 18 analysts are estimating revenue of $161.22M, an increase of 17.60% over than the figure of $17.10% in the same quarter last year. There is a high estimate of $166.58M for the next quarter, whereas the lowest estimate is $157.2M.
A total of 21 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $676M, while the lowest revenue estimate was $658.6M, resulting in an average revenue estimate of $664.39M. In the same quarter a year ago, actual revenue was $563.95M, up 17.80% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $808.72M in the next fiscal year. The high estimate is $869.9M and the low estimate is $760.6M. The average revenue growth estimate for next year is up 21.70% from the average revenue estimate for this year.
